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Abstract
Background: We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively
targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication
overuse (MO).
Methods: In a 12-week, phase 3 trial, patients with CM were randomized to fremanezumab quarterly (675 mg/
placebo/placebo), monthly (675 mg/225 mg/225 mg), or placebo. Post hoc analyses assessed the impact of
fremanezumab in patients with and without MO (monthly use of acute headache medication ≥15 days, migraine-
specific acute medication ≥10 days, or combination medication ≥10 days) on efficacy outcomes, including
headache days of at least moderate severity (HDs), and six-item Headache Impact Test (HIT-6) and Migraine-Specific
Quality of Life (MSQoL) questionnaire scores.
Results: Of 1130 patients enrolled, 587 (51.9%) had baseline MO. Fremanezumab reduced placebo-adjusted least-
squares mean (95% confidence interval) monthly HDs (− 2.2 [− 3.1 to − 1.2] and − 2.7 [− 3.7 to − 1.8]; P < 0.0001) in
patients with MO and without MO (quarterly − 1.4 [− 2.3 to − 0.5], P = 0.0026; monthly − 1.4 [− 2.3 to − 0.6],
P = 0.0017). Significantly more fremanezumab-treated patients had ≥ 50% reduction in HDs versus placebo,
regardless of baseline MO (with: quarterly 70/201 [34.8%], monthly 78/198 [39.4%] vs placebo 26/188 [13.8%];
without: quarterly 71/174 [40.8%], monthly 75/177 [42.4%] vs placebo 41/183 [22.4%]). Fremanezumab improved
HIT-6 and MSQoL scores. Significantly more fremanezumab-treated patients reverted to no MO (quarterly 111/201
[55.2%], monthly 120/198 [60.6%]) versus placebo (87/188 [46.3%]).
Conclusions: Fremanezumab is effective for prevention of migraine in patients with CM, regardless of MO, and
demonstrated a benefit over placebo in reducing MO.
Trial registration: ClinicalTrials.gov NCT02621931 (HALO CM), registered December 12, 2012.
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Background
Individuals with chronic migraine (CM) frequently use
acute headache medications, including triptans, ergot deriv-
atives, opioids, and simple and combination analgesics,
which can result in medication overuse (MO) [1, 2] and
lead to greater disability and further reduced quality of life
[1–5]. Preventive migraine therapy is recommended in pa-
tients with failure or overuse of acute medication, frequent
attacks (≥4 headache days per month), headaches that
interfere with daily routines despite acute treatment, or
adverse events associated with acute treatments [3, 6].
Despite the potential benefits, preventive therapy is often
underutilized [7, 8, 9], and persistence with treatment is
often poor due to lack of efficacy or intolerable side effects
[10–12]. New preventive therapies may improve patient
lives with superior treatment efficacy and tolerability
compared with previously available migraine preventive
therapies [12, 13].
Fremanezumab, a fully humanized monoclonal antibody
(IgG2Δa) that selectively targets calcitonin gene-related
peptide (CGRP), is approved in the United States and the
European Union for the preventive treatment of migraine
in adults [14, 15]. The 12-week, double-blind, placebo-
controlled, phase 3 HALO CM trial demonstrated that
subcutaneous administration of fremanezumab signifi-
cantly reduced headache days of at least moderate severity
in patients with CM [16]. To understand the impact of
fremanezumab in patients with MO, data from patients
with CM with and without MO were assessed post hoc to
examine the reduction of headache and migraine days and
acute headache medication use. Outcomes were also ex-
amined in patients who either did or did not revert from
MO at baseline to no MO during the study.
Methods
Standard protocol approvals, registrations, and patient
consents
The study (NCT02621931; https://clinicaltrials.gov/ct2/
show/NCT02621931) was conducted in accordance with
the International Conference for Harmonisation guide-
lines for Good Clinical Practice, the Declaration of
Helsinki, and relevant national and local regulations, and
it followed the established study protocol [16]. The
protocol was approved by relevant ethics committees
and institutional review boards, and written informed
consent was obtained from each patient prior to per-
forming any study procedures or assessments [16].
Study design, patients, and treatments
A description of the randomized, double-blind,
placebo-controlled, parallel-group phase 3 HALO CM
study (NCT02621931), which included a screening
visit, 28-day pretreatment period, 12-week treatment
period, and final evaluation (week 12), has been pub-
lished previously [16].
Briefly, adults aged 18 to 70 with a history of migraine
(according to the International Classification of Headache
Disorders, third edition [ICHD-3] beta criteria [17]) for
≥12months prior to screening and prospectively con-
firmed CM (headache on ≥15 days and ≥8 days fulfilling
ICHD-3 beta criteria for migraine, probable migraine, or
use of triptan or ergot medications) during the 28-day
pretreatment baseline period were eligible to participate
[16]. Patients who used opioids (including codeine) or bar-
biturates on >4 days per month were excluded from the
trial. Additional inclusion and exclusion criteria are pro-
vided in a Table in Additional file 1.
Eligible patients were randomized 1:1:1 to receive subcuta-
neous injections of either fremanezumab quarterly (675mg
of fremanezumab at baseline and placebo at weeks 4 and 8),
fremanezumab monthly (675mg of fremanezumab at base-
line and 225mg at weeks 4 and 8), or placebo (matching pla-
cebo at baseline and at weeks 4 and 8) [16].
Outcomes
The primary endpoint of the study, mean change from
baseline (28-day pretreatment period) in the monthly
average number of headache days of at least moderate se-
verity during the 12-week treatment period, has been pre-
viously described [16]. Herein, post hoc analyses were
conducted to assess the impact of fremanezumab in pa-
tients with and without MO. Patients were grouped based
on the presence or absence of baseline MO, which was de-
fined as use of acute headache medication on ≥15 days,
migraine-specific acute medication on ≥10 days, or com-
bination medications for headache on ≥10 days during the
28-day pretreatment period [17].
The following outcomes were assessed in patients with
and without MO based on mean change from baseline
(28-day pretreatment period) in the: monthly average
number of headache days of at least moderate severity
during the 12-week treatment period; monthly average
number of migraine days during the 12-week treatment
period; and monthly average number of days of any
acute headache medication use. Also assessed was the
proportion of patients with a ≥ 50% reduction from base-
line (28-day pretreatment period) in the monthly average
number of headache days of at least moderate severity
during the 12-week treatment period; mean change from
baseline (day 0) in scores on the six-item Headache Im-
pact Test (HIT-6; scores range from 36 to 78, with
higher scores indicating greater impact of headache on
functional status and well-being) [18] at 4 weeks after
the last dose of study drug; mean change from baseline
(day 0) in domain scores on the Migraine-Specific Qual-
ity of Life (MSQoL) questionnaire (domains assessed:
role function–restrictive [RFR; seven items on how
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migraines limit daily activities], role function–preventive
[RFP; four items on how migraines prevent these activ-
ities], emotional function [EF; three items on the emo-
tional effects of migraines]; scores range from 0 to 100,
with higher scores indicating better health-related quality
of life) [19] at 4 weeks after the last dose of study drug;
and mean change from baseline (day 0) in scores on the
nine-item Patient Health Questionnaire (PHQ-9; scores
range from 0 to 27, with depression severity categorized as
no or minimal [0 to 4], mild [5 to 9], moderate [10 to 14],
moderately severe [15 to 19], and severe [20 to 27]) [20] at
4 weeks after the last dose of study drug.
Additionally, patients with MO at baseline were assessed
for reversion to no MO, where reversion was defined as
no longer meeting criteria for MO over the 12-week
period, or continued MO during the 12-week treatment
period. Outcomes assessed in these subgroups included
those previously described.
Statistical analyses
The post hoc analyses reported here were performed on
subgroups of patients in the full analysis set (FAS) popula-
tion: randomized patients who received ≥1 dose of study
drug and had ≥10 days of post-baseline efficacy assess-
ments on the primary endpoint (i.e., a daily headache
diary) [16]. The subgroups included patients with MO at
baseline versus without MO at baseline; and patients who
did revert from MO at baseline to no MO during the
study versus patients who did not revert from MO at
baseline to no MO during the study. Least-square (LS)
mean changes from baseline were evaluated using an ana-
lysis of covariance with treatment, sex, region, and base-
line preventive migraine medication use as fixed effects,
and baseline values and years since onset of migraines as
covariates. The Cochran-Mantel-Haenszel test was used
to analyze treatment differences between proportions of
patients, with baseline preventive medication use as the
stratification variable. Patients who prematurely discontin-
ued from the study were considered as non-responders
for overall analysis. For subgroups defined by treatment
outcomes (i.e., patients who did or did not revert from
MO at baseline to no MO during the study), data were
summarized using descriptive statistics.
Results
Study population
A total of 1130 patients with CM were randomized to re-
ceive fremanezumab quarterly (n = 376), fremanezumab
monthly (n = 379), or placebo (n = 375). The criteria for
CM with MO at baseline were met by 201 (53.6%), 198
(52.8%), and 188 (50.7%) of the evaluable patients in the
fremanezumab quarterly, fremanezumab monthly, and
placebo groups, respectively. The demographics and clin-
ical characteristics of patients in each subgroup (with MO
and without MO) differed from each other in several ways,
most notably age, years since initial diagnosis, current pre-
ventive medication use, current use of triptans or ergots,
prior topiramate use, prior onabotulinumtoxinA use,
headache days of at least moderate severity, migraine days,
and days of acute headache medication use, although stat-
istical significance of differences between subgroups in in-
dividual characteristics was not tested (Table 1).
Monthly average number of headache days of at least
moderate severity with and without MO
Among patients with MO at baseline, the placebo-
adjusted LS mean (95% confidence interval [CI]) change
from baseline in the monthly average number of headache
days of at least moderate severity during the 12-week
treatment period was significantly greater with fremanezu-
mab quarterly (− 2.2 [− 3.1 to − 1.2]; P < 0.0001) and
monthly (− 2.7 [− 3.7 to − 1.8]; P < 0.0001) (Fig. 1a). Simi-
lar results were seen in patients without MO at baseline
(quarterly − 1.4 [− 2.3 to − 0.5], P = 0.0026; monthly − 1.4
[− 2.3 to − 0.6], P = 0.0017 vs placebo) (Fig. 1a).
Fremanezumab-treated patients with MO had numerically
greater reductions in the monthly average number of
headache days of at least moderate severity than patients
without MO and demonstrated a larger treatment effect
over placebo than those with MO.
Monthly average number of migraine days with and
without MO
The placebo-adjusted LS mean (95% CI) reduction from
baseline in monthly average number of migraine days in
patients with MO at baseline was significantly greater
with fremanezumab quarterly (− 2.0 [− 3.1 to − 1.0],
P = 0.0002) and monthly (− 2.4 [− 3.5 to − 1.4], P < 0.0001)
(Fig. 1b). Similar results were seen in patients without MO
at baseline (quarterly − 1.4 [− 2.5 to − 0.3], P = 0.0132;
monthly − 1.3 [− 2.4 to − 0.2], P = 0.0249 vs placebo])
(Fig. 1b). Numerically greater reductions in monthly average
number of migraine days from baseline and a larger treat-
ment difference over placebo were seen in fremanezumab-
treated patients with MO compared with patients without
MO.
Acute headache medication use days with and without MO
Treatment with fremanezumab resulted in significantly
greater reductions in the monthly average number of
days of any acute headache medication use compared
with placebo among patients with MO at baseline (LS
mean difference [95% CI]: quarterly − 1.8 [− 2.9 to − 0.8],
P = 0.0006; monthly − 2.4 [− 3.5 to − 1.4], P < 0.0001;
Fig. 1c) and patients without MO at baseline (quarterly
− 1.6 [− 2.4 to − 0.9], monthly − 2.3 [− 3.1 to − 1.6];
P < 0.0001 for both (Fig. 1c). Reductions from baseline in
monthly average number of days with any acute
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headache medication use and treatment difference over
placebo were numerically greater in fremanezumab-
treated patients with MO than in patients without MO.
≥ 50% reduction in the monthly average number of
headache days
The proportion of patients with a ≥ 50% reduction in the
monthly average number of headache days of at least mod-
erate severity was significantly greater among fremanezu-
mab quarterly and fremanezumab monthly groups
compared with placebo, regardless of MO at baseline (with
MO: quarterly 70/201 [34.8%, P < 0.0001], monthly 78/198
[39.4%, P < 0.0001] vs placebo 26/188 [13.8%]; without MO:
quarterly 71/174 [40.8%, P = 0.0003], monthly 75/177
[42.4%, P < 0.0001] vs placebo 41/183 [22.4%, Fig. 2). The
odds of achieving a ≥ 50% reduction (odds ratio [95% CI])
was greater with fremanezumab versus placebo in both pa-
tients with MO (quarterly 3.33 [2.01 to 5.52], monthly 4.08
[2.47 to 6.75]) and without MO (quarterly 2.37 [1.50 to
3.76], monthly 2.53 [1.60 to 4.00]).
Patient-reported outcomes with and without MO
During the 12-week treatment period, the LS mean
(standard error) change from baseline in HIT-6 scores
was significantly greater with fremanezumab versus pla-
cebo, regardless of MO at baseline (with MO: quarterly
LS mean − 6.0 [0.7], monthly − 6.9 [0.6] vs placebo − 4.5
[0.7]; Table 2; without MO: quarterly − 7.0 [0.7],
monthly − 6.8 [0.6] vs placebo − 4.5 [0.6]; Table 2).
Improvement in MSQoL domain scores was ob-
served in patients with MO (RFR: quarterly 19.6 [1.8],
monthly 21.4 [1.8] vs placebo 14.7 [1.9]; RFP: quar-
terly 17.5 [1.7], monthly 18.4 [1.6] vs placebo 14.2
[1.7]; EF: quarterly 20.2 [2.0], monthly 22.0 [1.9] vs
placebo 17.3 [2.0]; Table 2). In the fremanezumab
quarterly with MO group, the RFR domain score
change from baseline compared with placebo was sig-
nificant; the RFP and EF domain score changes were
not significantly different from placebo (Table 2). All
changes from baseline in MSQoL domain scores in
the fremanezumab monthly group were significantly
Table 1 Demographics and baseline characteristics with and without MOa














Age, mean (SD), y 44.6 (11.6) 44.8 (10.9) 45.0 (10.8) 39.0 (12.6) 36.2 (11.5) 37.7 (12.1)
Sex, female, n (%) 183 (91) 173 (87) 168 (89) 147 (84) 154 (87) 158 (86)
BMI, mean (SD), kg/m2 26.4 (5.3) 26.4 (5.0) 26.0 (5.0) 26.9 (5.5) 26.7 (5.3) 26.9 (5.1)
Disease history
Years since initial migraine diagnosis, mean (SD) 21.0 (12.7) 22.8 (12.3) 23.2 (13.8) 18.3 (12.9) 17.1 (11.0) 16.7 (11.0)
Current preventive medication use, n (%) 47 (23.4) 54 (27.3) 38 (20.2) 30 (17.2) 31 (17.5) 39 (21.3)
Current use of triptans or ergots, n (%) 141 (70.1) 138 (69.7) 128 (68.1) 67 (38.5) 49 (27.7) 64 (35.0)
Prior topiramate use, n (%) 65 (32.3) 72 (36.4) 77 (41.0) 41 (23.6) 43 (24.3) 40 (21.9)
Prior onabotulinumtoxinA use, n (%) 38 (18.9) 34 (17.2) 32 (17.0) 28 (16.1) 16 (9.0) 17 (9.3)
Disease characteristics during the 28-day pretreatment period
Number of headache days of at least moderate severity,b mean (SD) 15.5 (5.0) 14.9 (5.4) 14.8 (5.4) 10.5 (4.8) 10.5 (5.3) 11.7 (5.8)
Number of migraine days,c mean (SD) 17.2 (4.6) 17.5 (4.9) 17.3 (5.0) 15.0 (4.9) 14.3 (5.0) 15.4 (5.1)
Number of days of acute medication use, mean (SD) 18.1 (4.0) 18.4 (4.5) 18.2 (4.4) 7.4 (4.4) 7.1 (4.5) 7.7 (4.5)
HIT-6 score, mean (SD) 64.5 (5.1) 65.3 (4.4) 63.8 (5.2) 64.0 (4.3) 63.9 (4.3) 64.3 (4.4)
PHQ-9 score, mean (SD) 4.3 (5.5) 5.9 (6.7) 3.7 (5.7) 4.1 (5.6) 4.0 (5.6) 4.0 (5.6)
MSQoL domain scores
RFR, mean (SD) 49.1 (18.9) 46.8 (19.7) 49.7 (20.5) 48.2 (18.3) 49.7 (18.7) 48.8 (19.2)
RFP, mean (SD) 67.5 (21.1) 63.2 (23.5) 67.5 (22.9) 67.1 (20.4) 68.7 (20.6) 67.4 (21.7)
EF, mean (SD) 58.4 (26.2) 54.3 (27.1) 58.0 (27.5) 55.8 (26.9) 60.4 (25.1) 57.7 (25.4)
BMI Body mass index, CM Chronic migraine, EF Emotional function, HIT-6 Six-item Headache Impact Test, MO Medication overuse, MSQoL Migraine-Specific Quality
of Life, RFP Role function−preventive, RFR Role function−restrictive, SD Standard deviation
aMO was defined as use of acute headache medication on ≥ 15 days, migraine-specific acute medication on ≥ 10 days, or combination medication for headache on
≥ 10 days during the 28-day pretreatment period. bA headache day of at least moderate severity was defined as a calendar day in which headache pain lasted at least 4
consecutive hours and had a peak severity of at least a moderate level, or a day in which acute migraine-specific medication (triptan or ergot) was used to treat a
headache of any severity or duration. cA migraine day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and met criteria for
migraine (with or without aura) or probable migraine (subtype in which only one migraine criterion is absent), or a day in which acute migraine-specific medication
(triptan or ergot) was used to treat a headache of any duration.
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different compared with placebo (Table 2). Similarly,
in patients without MO, improvements in MSQoL
domain scores were observed (RFR: quarterly 21.9
[2.0], monthly 21.6 [2.0] vs placebo 14.5 [1.9]; RFP:
quarterly 16.4 [1.7], monthly 14.2 [1.7] vs placebo
10.2 [1.7]; EF: quarterly 22.4 [2.1], monthly 19.7 [2.1]
vs placebo 16.7 [2.1]; Table 2). All MSQoL domain
scores in the fremanezumab quarterly without MO
group were significantly different compared with pla-
cebo (Table 2). In the fremanezumab monthly with-
out MO group, RFR and RFP domain score changes
from baseline were significant compared with placebo;
Fig. 1 Change in days with (a) headache, (b) migraine, and (c) medication use in patients with CM by MO. Values shown are the mean changes
from baseline in the monthly average number of (a) headache days of at least moderate severity, (b) migraine days, and (c) acute headache
medication use during the 12-week treatment period with and without MO. CM, chronic migraine; LSM, least-squares mean; MO, medication
overuse; SE, standard error
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no significant difference in the EF domain score was
observed (Table 2).
Reductions in PHQ-9 scores were observed, regardless of
MO at baseline (with MO: quarterly − 2.8 [0.4], monthly
− 2.3 [0.4] vs placebo − 2.4 [0.4]; without MO: quarterly
− 2.6 [0.4], monthly − 2.3 [0.4] vs placebo − 1.6 [0.4];
Table 2). Numerically larger reductions were generally ob-
served in the fremanezumab-treated groups compared with
placebo; however, the only significant difference was ob-
served in patients without MO in the fremanezumab quar-
terly group compared with placebo (Table 2).
Reversion from MO to no MO
Among CM patients with baseline MO, significantly
greater proportions of patients treated with fremanezu-
mab quarterly or monthly reverted to no MO during the
12-week treatment period (quarterly 111/201 [55.2%],
P = 0.0389; monthly 120/198 [60.6%], P = 0.0024) than
those who received placebo (87/188 [46.3%]) (Fig. 3).
This effect was present by week 4 (quarterly 102/201
[50.7%], monthly 107/198 [54.0%] vs placebo 73/188
[38.8%]).
Similar baseline mean (standard deviation) monthly
average number of days of acute headache medication use
were observed across treatment arms within the subgroup
of patients who reverted from MO (quarterly 16.6 [3.4],
monthly 16.7 [3.6], placebo 16.6 [3.3]) and the subgroup
of patients who continued MO (quarterly 19.9 [3.9],
monthly 21.0 [4.5], placebo 19.5 [4.8]), though numerically
greater numbers were observed among patients who con-
tinued MO. Among patients who reverted from MO at
baseline, the reduction from baseline in the monthly
average number of days of acute headache medication use
was − 9.0 (0.4) with fremanezumab quarterly, − 8.9 (0.4)
with fremanezumab monthly, and − 7.1 (0.5) with placebo
(Fig. 4a). In comparison, patients with continued MO ex-
perienced numerically smaller reductions in the monthly
average number of days of acute medication use in both
the fremanezumab-treated groups (quarterly − 1.7 [0.4],
monthly: − 2.2 [0.4]) and the placebo group (− 1.1 [0.4];
Fig. 4a).
Furthermore, more than half of the patients who
reverted from MO achieved a ≥ 50% reduction in the
monthly average number of headache days of at least
moderate severity after treatment with fremanezumab
quarterly (66/111 [59.5%]) or monthly (67/120 [55.8%]); of
those treated with placebo, 27.6% (24/87) achieved a
≥ 50% reduction (Fig. 4b). Among patients who continued
to experience MO, the proportion of patients with a ≥ 50%
reduction in the monthly average number of headache
days of at least moderate severity was 4.4% (4/90) with fre-
manezumab quarterly, 14.1% (11/78) with fremanezumab
monthly, and 2.0% (2/101) with placebo (Fig. 4b).
Discussion
These post hoc analyses demonstrated that fremanezumab,
compared with placebo, significantly reduced the monthly
average number of headache days of at least moderate sever-
ity and led to a significantly greater proportion of patients
who had a clinically meaningful ≥ 50% response rate, inde-
pendently of the presence of MO in patients with CM. Simi-
lar reductions were also seen for migraine days. In patients
with baseline MO, significantly more fremanezumab-treated
patients reverted to no MO during the 12-week treatment
Fig. 2 Proportion of patients with CM with ≥ 50% response (a) with MO and (b) without MO. A≥ 50% response was defined as ≥ 50% reduction
from baseline in the monthly average number of headache days of at least moderate severity over 12 weeks. CM, chronic migraine;
MO, medication overuse
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period compared with those who received placebo. Signifi-
cant reductions in days using acute headache medication
were also observed in patients with and without MO at base-
line, with the greatest numerical reductions noted in those
who reverted from MO to no MO during the 12-week treat-
ment period.
Migraine preventive therapy is recommended for pa-
tients with frequent and chronic migraine, but the effect-
iveness of preventive medications was believed to be
affected by MO [6]. Topiramate, a migraine preventive
treatment, significantly reduced migraine days in pa-
tients with CM, but failed to reach significance in a post
hoc analysis of patients with CM and MO, possibly due
to a small sample size [21]. In one study of patients with
MO who were unresponsive to preventive therapy, with-
drawal of the overused medication increased the efficacy
of preventive therapy [22]. However, in our study, more
patients treated with fremanezumab had a ≥ 50% reduc-
tion in the monthly number of headache days of at least
moderate severity, independent of baseline MO. This
strongly suggests that MO has minimal, if any, impact
on the efficacy of fremanezumab.
Notable differences were observed between patients
with and without MO at baseline, including several dif-
ferences in disease characteristics. By definition, monthly
number of days using acute headache medication dif-
fered between subgroups. The defining feature of the sub-
groups may also underlie the differences in monthly
number of headache days of at least moderate severity and
migraine days, because a day with acute migraine-specific
medication use to treat a headache of any severity or dur-
ation was included in the count for these variables. Dis-
ease characteristics that did not notably differ at baseline
included levels of disability, quality of life, and depression
as measured by HIT-6, MSQoL domain, and PHQ-9
scores, respectively. Previous studies have shown that pa-
tients with chronic daily headache (CDH; an umbrella
term that encompasses CM) and MO have more disability
and quality-of-life impairment compared with patients
with CDH without MO; however, because these studies
Table 2 Change from baseline in patient-reported outcome measures with and without MO















LSM (SE) −6.0 (0.7) −6.9 (0.6) −4.5 (0.7) −7.0 (0.7) − 6.8 (0.64) −4.5 (0.6)
LSMD (SE) − 1.5 (0.7) −2.4 (0.7) −2.4 (0.7) − 2.3 (0.7)
P value 0.0356 0.0009 0.0006 0.0012
MSQoL, RFR
LSM (SE) 19.6 (1.8) 21.4 (1.8) 14.7 (1.9) 21.9 (2.0) 21.6 (2.0) 14.5 (1.9)
LSMD (SE) 4.9 (2.0) 6.7 (2.0) 7.4 (2.1) 7.1 (2.1)
P value 0.0142 0.0008 0.0005 0.0008
MSQoL, RFP
LSM (SE) 17.5 (1.7) 18.4 (1.6) 14.2 (1.7) 16.4 (1.7) 14.2 (1.7) 10.2 (1.7)
LSMD (SE) 3.2 (1.8) 4.2 (1.8) 6.2 (1.8) 3.9 (1.8)
P value 0.0696 0.0200 0.0007 0.0290
MSQoL, EF
LSM (SE) 20.2 (2.0) 22.0 (1.9) 17.3 (2.0) 22.4 (2.1) 19.7 (2.1) 16.7 (2.1)
LSMD (SE) 2.9 (2.2) 4.7 (2.2) 5.7 (2.3) 3.0 (2.3)
P value 0.1833 0.0305 0.0118 0.1873
PHQ-9
LSM (SE) −2.8 (0.4) −2.3 (0.4) −2.4 (0.4) −2.6 (0.4) −2.3 (0.4) −1.6 (0.4)
LSMD (SE) −0.5 (0.4) 0.0 (0.4) −1.0 (0.4) −0.7 (0.4)
P value 0.2679 0.9678 0.0155 0.0922
CM Chronic migraine, EF Emotional function, HIT-6 Six-item Headache Impact Test, LSM Least-squares mean, LSMD Least-squares mean difference, MO Medication
overuse, MSQoL Migraine-Specific Quality of Life, RFP Role function–preventive, RFR Role function–restrictive, PHQ-9 Patient Health Questionnaire-9,
SE Standard error
LSMD was determined in comparison to placebo
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looked at MO in a heterogenous group of headache disor-
ders, they may not be generalizable to patients with CM
[1]. Similarly to CM, medication overuse headache, a sec-
ondary headache attributable to MO, is associated with
psychiatric comorbidities such as depression, although
whether it could be a cause or an effect is not known [23,
24]. Baseline characteristics in this study suggest that MO
does not increase the severity of depression in patients
with CM. The impact of fremanezumab on disability,
quality of life, and depression was positive in patients with
and without MO, with significant differences from placebo
observed for HIT-6 and MSQoL domain scores. PHQ-9
scores were reduced from baseline; however, only the re-
duction among patients without MO in the
fremanezumab quarterly group reached statistical signifi-
cance. A greater difference over placebo may not have
been observed due to the majority of patients (69.1% to
79.2%) already having PHQ-9 scores in the no to minimal
depression range (R.B. Lipton, unpublished data, 2019),
creating a floor effect. In a separate subgroup analysis of
patients in this population with moderate to severe depres-
sion, reductions in mean PHQ-9 scores were numerically
greater, although not statistically significant, potentially due
to the modest sample size (R.B. Lipton, unpublished data,
2019).
In this study, patients with MO saw improvements in
the measured outcomes without undergoing withdrawal
therapy or so-called “detoxification,” which is often be-
lieved to be important in managing MO [2]. Several strat-
egies are available for detoxification, including early
abrupt withdrawal, restricted intake, discontinuation ther-
apy with rescue medication (different analgesic than the
overused medication), or intravenous hydration [2, 3, 25].
During detoxification, most patients experience an initial
worsening of headaches and additional withdrawal symp-
toms such as nausea, vomiting, hypotension, tachycardia,
sleep disturbances, restlessness, and anxiety, which typic-
ally last up to 10 days, but may persist for up to 4 weeks
[3, 26, 27]. Studies have demonstrated variable rates of
success in discontinuing medications, with percentages of
patients achieving detoxification ranging from 57% to
100% [28]. Even after successful discontinuation of over-
used medication, 17% to 43% of patients relapse back to
MO just 1 year after detoxification [28]. Our results sug-
gest that patients treated with fremanezumab do not need
to discontinue overused drugs to experience the benefit of
preventive treatment and achieve reduced acute medica-
tion use. Fremanezumab treatment resulted in 58% of
Fig. 3 Proportion of patients with CM who reverted from MO to no
MO during the 12-week treatment period. CM, chronic migraine;
MO, medication overuse
Fig. 4 (a) Reduction in medication use and (b) ≥ 50% response in patients with CM by reversion to no MO. Values shown in part A are mean
(SE) change from baseline over 12 weeks in the monthly average number of days of acute medication use in patients who reverted from MO to
no MO (blue bars) and in those who did not revert from MO to no MO (green bars). Values shown in part B are the proportions of patients with
a ≥ 50% response, defined as a ≥ 50% reduction in the monthly average number of headache days of at least moderate severity from baseline
over 12 weeks, in patients who reverted from MO to no MO (blue bars) and in those who did not revert from MO to no MO (green bars).
CM = chronic migraine; MO =medication overuse; SE = standard error
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patients reverting from MO to no MO, compared with
46% for patients given placebo, suggesting that patients re-
ceiving fremanezumab may achieve reversion from MO,
avoid detoxification and its associated symptoms, and still
achieve fewer headache days and migraine days. Together,
this suggests the potential for a paradigm shift to an ef-
fective and more humane approach for treating CM with
MO: prevent first and detoxify later if necessary.
These findings have certain limitations. These subgroup
analyses were not prespecified in the HALO CM protocol;
however, the measures evaluated were generally consistent
with the observed effects in the FAS population, and all
data points in these subgroups were collected a priori. In
addition, this study did not consider the intensity of MO,
differentiate between the types or combination of medica-
tions taken, nor did it consider the presence and severity of
comborbid psychiatric disorders that may contribute to
MO, such as anxiety or cephalophobia. Future studies to
determine whether the type of overused medication im-
pacts outcomes would be beneficial. Due to exclusion cri-
teria, patients using opioids or barbiturates on more than
4 days per month were not included in this trial; therefore,
inferences cannot be drawn about patients overusing these
drugs. Furthermore, one cannot rule out that the routine
observation by doctors over the course of the trial may have
contributed to some of the observed reductions in MO;
however, placebo-treated patients were observed in a simi-
lar manner with smaller improvements. The current un-
derstanding of the pathophysiology of MO also
supports the role of fremanezumab in reducing MO.
Increased CGRP expression and release is hypothesized
to play a role in the development of the increased sensi-
tivity to pain perception that MO fosters [29, 30]. This
sensitization may be reversed by blocking CGRP with
fremanezumab. In triptan- or morphine-sensitized rats,
a single administration of fremanezumab was able to
prevent cutaneous allodynia resulting from triggers as-
sociated with migraine attacks [31]. Lastly, headache
data were captured using a patient self-reported diary,
which can vary in terms of content recorded, reading
and writing skill, and compliance.
Conclusion
Results from these post hoc analyses demonstrated that
fremanezumab was efficacious in the preventive treat-
ment of patients with CM regardless of the presence of
MO and increased the likelihood of reversion from
medication overuse to no medication overuse.
Supplementary information
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